Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10729425 | 0.86 | IDO1 (0.53) | IDO1PDPK1ADRA1A | |
| SCHEMBL11671198 | 0.75 | SRD5A1 (0.55) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL29263189 | 0.73 | IDO1 (0.52) | IDO1PDPK1CYP11B2RETHTR2A | |
| Magnesium SCHEMBL31510119 | 0.73 | SRD5A1 (0.53) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL8679389 | 0.73 | IDO1 (0.52) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL10633202 | 0.73 | IDO1 (0.52) | IDO1PDPK1CYP11B2ADRA1ARET | |
| SCHEMBL503849 | 0.73 | SIGMAR1 (0.62) | CYP11B2ADRA1AHTR2ASIGMAR1 | |
| SCHEMBL6667045 | 0.73 | IDO1 (0.47) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL29390302 | 0.73 | SIGMAR1 (0.62) | CYP11B2ADRA1AHTR2ASIGMAR1 | |
| SCHEMBL23343810 | 0.71 | IDO1 (0.50) | IDO1PDPK1CYP11B2RETHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093759-A1 | Medical Devices, Wound Dressings, and Methods for Dressing Wounds | VACHON DAVID J (US) | 2012-04-19 | — | — | US | claimed |
| US-20260076977-A1 | METHODS FOR TREATMENT OF DISEASES | GALERA LABS LLC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025051102-A1 | DEUTERATED TETRACYCLIC DERIVATIVE AND USE THEREOF | 浙江我武翼方药业有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119591611-A | Deuterated tetracyclic derivative and application thereof | 浙江我武翼方药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20250017944-A1 | METHODS FOR TREATMENT OF DISEASES | GALERA LABS, LLC | 2025-01-16 | — | — | US | disclosed |
| US-12151028-B2 | Drug delivery systems comprising solid solutions of weakly basic drugs | ADARE PHARMACEUTICALS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240335376-A1 | GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY | AMNEAL COMPLEX PRODUCTS RESEARCH LLC (US) | 2024-10-10 | — | — | US | disclosed |
| US-12042559-B2 | Gastroretentive dosage forms for sustained drug delivery | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240000701-A1 | SELF-REGULATING OSMOTIC GASTRORETENTIVE DRUG DELIVERY SYSTEMS | AMNEAL COMPLEX PRODUCTS RESEARCH LLC (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230404916-A1 | GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY | AMNEAL COMPLEX PRODUCTS RESEARCH LLC (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2002072034-A2 | CHRONOTHERAPEUTIC DOSAGE FORMS | PENWEST PHAMACEUTICALS CO. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2002007707-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | PERICOR SCIENCE, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001098317-A2 | ALPHA-GLYCOSYLCERAMIDES FOR TREATING BACTERIAL AND FUNGAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1159293-A1 | BACTERIAL TRANSGLYCOSYLASES: ASSAYS FOR MONITORING THE ACTIVITY USING LIPID II SUBSTRATE ANALOGS AND METHODS FOR DISCOVERING NEW ANTIBIOTICS | PRINCETON UNIVERSITY (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000052035-A1 | BACTERIAL TRANSGLYCOSYLASES: ASSAYS FOR MONITORING THE ACTIVITY USING LIPID II SUBSTRATE ANALOGS AND METHODS FOR DISCOVERING NEW ANTIBIOTICS | PRINCETON UNIVERSITY (US) | 2000-09-08 | — | — | WO | disclosed |
| US-5378474-A | Pellet having a core including at least one highly soluble active ingredient and a coating partially soluble at high acidity; opiod drugs | F. H. FAULDING & CO. LIMITED (AU) | 1995-01-03 | — | — | US | disclosed |
| US-5330766-A | Water soluble active ingredient core coated with matrix and enteric polymers; high speed, uniform release | F. H. FAULDING & CO. LIMITED (AU) | 1994-07-19 | — | — | US | disclosed |
| US-5202128-A | Oral administering | F. H. FAULDING & CO. LIMITED (AU) | 1993-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017944-A1 | METHODS FOR TREATMENT OF DISEASES | SOD1, GLS, GLS2 | IDO1 3832/4885PDPK1 4040/4885CYP11B2 132/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | IDO1 61/4885PDPK1 3923/4885CYP11B2 3104/4885 |
| US-20260076977-A1 | METHODS FOR TREATMENT OF DISEASES | SOD1, SOD3, CAT | IDO1 3153/4885PDPK1 4735/4885CYP11B2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.